Keywords: cyclacel, cancer, drug, starts, phase, ii, testing
Cyclacel's cancer drug starts Phase II testing
Article | 27 January 2003
Dundee, UK-based Cyclacel has started enrolling patients into twoPhase IIa studies of CYC202 (R-roscovitine), its orally-active inhibitor of cyclin-dependent kinase. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
